Outlook Therapeutics (OTLK) Income from Continuing Operations: 2015-2020
Historic Income from Continuing Operations for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$9.9 million.
- Outlook Therapeutics' Income from Continuing Operations rose 1.73% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$38.3 million, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- According to the latest figures from Q3 2020, Outlook Therapeutics' Income from Continuing Operations is -$9.9 million, which was down 229.09% from -$3.0 million recorded in Q2 2020.
- In the past 5 years, Outlook Therapeutics' Income from Continuing Operations registered a high of -$1.9 million during Q4 2017, and its lowest value of -$22.3 million during Q2 2016.
- For the 3-year period, Outlook Therapeutics' Income from Continuing Operations averaged around -$9.2 million, with its median value being -$9.7 million (2018).
- As far as peak fluctuations go, Outlook Therapeutics' Income from Continuing Operations skyrocketed by 89.94% in 2017, and later slumped by 407.26% in 2018.
- Over the past 5 years, Outlook Therapeutics' Income from Continuing Operations (Quarterly) stood at -$19.1 million in 2016, then spiked by 89.94% to -$1.9 million in 2017, then tumbled by 407.26% to -$9.7 million in 2018, then rose by 9.86% to -$8.8 million in 2019, then climbed by 1.73% to -$9.9 million in 2020.
- Its last three reported values are -$9.9 million in Q3 2020, -$3.0 million for Q2 2020, and -$16.6 million during Q1 2020.